Steffen Heeger

Mannheim, BW, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.

Evaluation of EGFR inhibitor-mediated acneiform skin toxicity within the double-blind randomized EVITA trial: A thorough gender-specific analysis using the WoMo score.

Journal: Cancer medicine

Published: March 05, 2019

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.

Vitamin K1 cream significantly reduces incidence and severity of cetuximab-related acneiform skin rash in women: a post hoc analysis of the EVITA trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: October 12, 2018

EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.

EVITA-a double-blind, vehicle-controlled, randomized phase II trial of vitamin K1 cream as prophylaxis for cetuximab-induced skin toxicity.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: January 24, 2018

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Use of early tumor shrinkage to predict long-term outcome in metastatic colorectal cancer treated with cetuximab.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: September 18, 2013

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.

A review of the treatment options for skin rash induced by EGFR-targeted therapies: Evidence from randomized clinical trials and a meta-analysis.

Journal: Radiology and oncology

Published: November 15, 2012

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

A phase I pharmacokinetic study of matuzumab in combination with paclitaxel in patients with EGFR-expressing advanced non-small cell lung cancer.

Journal: Investigational new drugs

Published: May 23, 2012

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.

Phase I study of matuzumab in combination with 5-fluorouracil, leucovorin and cisplatin (PLF) in patients with advanced gastric and esophagogastric adenocarcinomas.

Journal: Investigational new drugs

Published: April 24, 2012

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials.

Journal: European journal of cancer (Oxford, England : 1990)

Published: February 16, 2012

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

Prognostic factors in patients with advanced non-small cell lung cancer: data from the phase III FLEX study.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: December 07, 2011

Showing 1-9 of 9

Last Updated: 09/26/2026